David Morrow to Cardiovascular Diseases
This is a "connection" page, showing publications David Morrow has written about Cardiovascular Diseases.
Connection Strength
0.607
-
Biomarkers and Clinical Cardiovascular Outcomes With Ezetimibe in the IMPROVE-IT Trial. J Am Coll Cardiol. 2019 08 27; 74(8):1057-1068.
Score: 0.135
-
Classification of Deaths in Cardiovascular Outcomes Trials. Circulation. 2019 02 12; 139(7):874-876.
Score: 0.130
-
Baseline adiponectin concentration and clinical outcomes among patients with diabetes and recent acute coronary syndrome in the EXAMINE trial. Diabetes Obes Metab. 2017 07; 19(7):962-969.
Score: 0.114
-
Impact of biomarkers, proteomics, and genomics in cardiovascular disease. Clin Chem. 2012 Jan; 58(1):1-2.
Score: 0.079
-
American Heart Association COVID-19 CVD Registry Powered by Get With The Guidelines. Circ Cardiovasc Qual Outcomes. 2020 08; 13(8):e006967.
Score: 0.036
-
A current review of COVID-19 for the cardiovascular specialist. Am Heart J. 2020 08; 226:29-44.
Score: 0.035
-
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. J Am Coll Cardiol. 2018 03 06; 71(9):1021-1034.
Score: 0.030
-
2017 Cardiovascular and Stroke Endpoint Definitions for Clinical Trials. Circulation. 2018 02 27; 137(9):961-972.
Score: 0.030
-
Racial and Ethnic Differences in Presentation and Outcomes for Patients Hospitalized With COVID-19: Findings From the American Heart Association's COVID-19 Cardiovascular Disease Registry. Circulation. 2021 06 15; 143(24):2332-2342.
Score: 0.009
-
Efficacy and safety of more potent antiplatelet therapy with vorapaxar in patients with impaired renal function. J Thromb Thrombolysis. 2019 Apr; 47(3):353-360.
Score: 0.008